Skip to main content

Table 1 Univariable analysis of independent factors to maturation of AVF

From: Development of prognostic model for fistula maturation in patients with advanced renal failure

Clinical characteristics

Mature AVF %

Total %

Crude OR (95% CI)

p value

Age

   

0.45

 > 50 years

57.2

76.3

  

 ≤ 50 years

52.1

23.7

0.814 (0.477–1.389)

 

Gender

   

0.049*

 Male

60

66.7

  

 Female

48

33.3

0.615 (0.379–0.998)

 

Arm

   

0.129*

 Left

53.4

73.7

  

 Right

63.3

26.3

1.505 (0.887–2.553)

 

Fistula

   

0.115*

 BC

60.1

62.7

  

 RC

51.9

27

0.715 (0.423–1.208)

 

 BB

41.9

10.3

0.479 (0.222–1.036)

 

Surgeons

   

0.788

 Surgeon A

56.4

68.0

  

 Surgeon B

56

25.0

0.985 (0.578–1.679)

 

 Surgeon C

71.4

2.3

1.935 (0.367–10.206)

 

 Surgeon D

40

1.7

0.516 (0.084–3.154)

 

 Surgeon E

44.4

3

0.619 (0.162–2.373)

 

PVD

   

0.001*

 Yes

33.3

16

  

 No

60.3

84

3.04 (1.585–5.829)

 

DM

   

0.102*

 Yes

50

38

  

 No

59.7

62

1.48 (0.925–2.367)

 

Smoker

   

0.49

 Yes

61

13.7

  

 No

55.2

86.3

0.789 (0.402–1.547)

 

HTN

   

0.406

 Yes

57.3

78

  

 No

51.5

22

0.793 (0.458–1.371)

 

Dialysis

   

0.513

 Yes

53.6

37.3

  

 No

57.4

62.7

1.17 (0.731–1.873)

 

K+ (mmol/L)

   

0.948

 Normal

56.2

54.3

  

 Abnormal

55.8

45.7

1.015 (0.642–1.605)

 

Na+ (mmol/L)

   

0.439

 Normal

55.1

85.3

  

 Abnormal

61.4

14.7

1.295 (0.673–2.494)

 

Ca++ (mmol/L)

   

0.525

 ≤ 2.5

56.7

87

  

 > 2.5

51.3

13

0.804 (0.41–1.577)

 

HCO3 (mmol/L)

   

0.743

 ≤ 23

57

45

  

 > 23

55.2

55

0.926 (0.586–1.465)

 

Creatinine (mmol/L)

   

0.676

 > 400

57.5

44.7

  

 > 120 ≤ 400

55.2

54.3

0.913 (0.576–1.447)

 

 ≤ 120

33.3

1

0.37 (0.033–4.182)

 

Urea (mmol/L)

   

0.949

 > 15

55.3

65.7

  

 > 6.6–≤ 15

57.1

18.7

1.076 (0.591–1.960)

 

 ≤ 6.6

57.4

15.7

1.09 (0.73–2.073)

 

eGFR (ml/min/1.73m2)

   

0.459

 ≤ 15

57.4

64.6

  

 > 15

52.9

35.4

0.834 (0.516–1.349)

 

SBP (mm of Hg)

   

0.101*

 ≤ 130

51.6

53

  

 > 130

48.4

47

1.468 (0.927–2.325)

 

DBP (mm of Hg)

   

0.786

 ≤ 85

56.3

90.7

  

 > 85

53.6

9.3

0.897 (0.411–1.958)

 

BMI (kg/m2)

   

0.563

 ≤ 30

55

73.3

  

 > 30

58.8

26.7

1.165 (0.694–1.957)

 

PT (s)

   

0.413

 ≤ 13.4

56.9

86.6

  

 > 13.5

50

13.4

0.757 (0.389–1.474)

 

INR (ratio)

   

0.140*

 ≤ 1.2

57.6

88

  

 > 1.2

44.4

12

0.589 (0.292–1.189)

 

TC (mmol/L)

   

0.24*

 ≤ 5

57.9

76

  

 > 5

50

24

1.294 (0.804–2.084)

 

TG (mmol/L)

   

0.289

 ≤ 2.1

53.7

63.3

  

 > 2.1

60

36.7

0.773 (0.48–1.244)

 

HDL (mmol/L)

   

0.874

 ≤ 1.1

55.6

51

  

 > 1.1

56.5

49

1.037 (0.658–1.637)

 

Vein size (mm)

   

< 0.001*

 ≤ 2.5

26.3

12.6

  

 > 2.5

60.3

87.4

4.254 (1.983–9.126)

 
  1. Independent patient factors and blood markers that underwent in univariate analysis and their association with the maturation of AVF. Data values are expressed as value (%), odds ratio (OR), confidence interval (CI) and level of significance (p)
  2. BC brachiocephalic, RC radiocephalic, BB bicarbonate, PVD peripheral vascular disease, DM diabetes mellitus, HTN hypertension, K potassium, Na sodium, Ca calcium, HCO3 bicarbonate, e-GFR estimated glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, PT prothrombin time, INR international normalization ratio, TC total cholesterol, TG triglyceride, HDL high density lipoprotein
  3. *Significant variables having p value < 0.25
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us